AstraZeneca PLC (AZN.L)
-LSE 3,317.00 
17.00(0.51%) 11:35AM EDT
| Prev Close: | 3,334.00 |
|---|
| Open: | 3,317.50 |
|---|
| Bid: | 3,316.50 |
|---|
| Ask: | 3,317.50 |
|---|
| 1y Target Est: | 49.06 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3,293.00 - 3,349.50 |
|---|
| 52wk Range: | 2,578.50 - 3,403.50 |
|---|
| Volume: | 2,764,967 |
|---|
| Avg Vol (3m): | 2,506,580 |
|---|
| Market Cap: | 41.46B |
|---|
| P/E (ttm): | 733.69 |
|---|
| EPS (ttm): | 4.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- Veeva Systems planning initial public offering: sourcesat Reuters(Tue, Apr 30)
- Veeva Systems planning initial public offering: sourcesReuters(Tue, Apr 30)
- Veeva Systems planning initial public offering - sourcesat Reuters(Tue, Apr 30)
- Is AstraZeneca the Ultimate Stock Picker's Share?at Motley Fool(Mon, Apr 29)
- PRESS DIGEST - British Business - April 26at Reuters(Thu, Apr 25)
- Profits Dive 31% at AstraZenecaat Motley Fool(Thu, Apr 25)
- [$$] No Parachute for AstraZenecaat The Wall Street Journal(Thu, Apr 25)
- Why Unilever, AstraZeneca, and Kier Group Should Lag the FTSE 100 Todayat Motley Fool(Thu, Apr 25)
- AstraZeneca Q1 net profit plunges 31 percentAP(Thu, Apr 25)
- Bristol net plunges 45 pct. on generic competitionAP(Thu, Apr 25)
- Q1 2013 AstraZeneca PLC Earnings Release - 02:00 am ETCCBN(Thu, Apr 25)
- [$$] Mixed Results for Drug Companiesat The Wall Street Journal(Thu, Apr 25)
- UPDATE 2-AstraZeneca hit by generic drugs and Crestor shortfallat Reuters(Thu, Apr 25)
- AstraZeneca gets U.S. subpoena over UK drug factoryat Reuters(Thu, Apr 25)
- BRIEF-Astra CFO sees U.S. Brilinta growth accelerating at back-end of yearat Reuters(Thu, Apr 25)
Key Statistics
| Forward P/E (1 yr): | 6.37 |
|---|
| P/S (ttm): | 154.30 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.38 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.22 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -1.21 |
|---|
Business Summary
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide.
View More